Last reviewed · How we verify
NCT05811039: Remo_Itch
Efficacy and Safety of Remo-Wax® Oil (RWO) in Subjects With Isolated Itching of the External Ear Canal
NA trial testing Remo-Wax® Oil in Itching in 36 participants. Completed in 5 October 2023.
5 October 2023
Quick facts
| Lead sponsor | Orion Corporation, Orion Pharma |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 36 |
| Start date | 17 May 2023 |
| Primary completion | 5 October 2023 |
| Estimated completion | 5 October 2023 |
| Sites | 1 location across Lithuania |
Drugs / interventions tested
- Remo-Wax® Oil
Conditions studied
- Itching — all drugs for Itching →
Sponsor
Orion Corporation, Orion Pharma — full company profile →
Who can join
12 and older, any sex, with Itching. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Open, single-arm, non-randomized study to demonstrate the efficacy of Remo-Wax® Oil (abbreviated RWO) in the treatment of isolated itching of the external ear canal and to demonstrate the safety of the product.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT05811039
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Itching
Currently open trials in the same condition.
- NCT07017231 — Role of Interleukin-13 Pathways on Pain and Itch Sensitivity ( IL-13 ) · NA · active not recruiting
- NCT06704698 — Postoperative Analgesia Between Paravertebral Block and Epidural Block in Esophageal Surgery · NA · recruiting
- NCT06104540 — Comparison of the Effects of Liquid Vaseline and Olive Oil on Itching and Scarring in Scald Burns · NA · recruiting
Other Orion Corporation, Orion Pharma trials
Trials by the same sponsor.
- NCT06725758 — A Phase 1/2, First-in-Human Study On ODM-212 In Subjects With Selected Advanced Solid Tumours · Phase 1, PHASE2 · recruiting
- NCT06956495 — Efficacy and Tolerability of Tasipimidine in Sleepless Patients · Phase 2 · completed
- NCT05288075 — Study to Compare Relative Bioavailability of 3 Indacaterol/Glycopyrronium Test Products and Reference Product · Phase 1 · completed
- NCT05246046 — Comparison of Tiotropium Absorption From Tiotropium Easyhaler and Spiriva HandiHaler · Phase 1 · completed
- NCT05084222 — Use of Buventol Easyhaler and Bufomix Easyhaler in Methacoline Challenge Testing · Phase 4 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05811039 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Orion Corporation, Orion Pharma
- Last refreshed: 6 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05811039.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing